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Ataluren in cystic fibrosis: development, clinical studies and where are we now? 
 
1 Abstract 
 
Introduction: Cystic fibrosis (CF) is one of the most common genetically-acquired life-limiting 
conditions worldwide. The underlying defect is dysfunction of the cystic fibrosis transmembrane-
conductance regulator (CFTR) which leads to progressive lung disease and other multi-system 
effects. Around 10% of people with CF have a class I nonsense mutation that leads to production 
of shortened CFTR due to a premature termination codon (PTC). 
Areas covered: We discuss the discovery of the small-molecule drug ataluren, which in vitro has 
been shown to allow read-through of PTCs and facilitate synthesis of full-length protein. We review 
clinical studies that have been performed involving ataluren in CF. Early-phase short-term cross-
over studies showed improvement in nasal potential difference. A follow-up phase III randomised 
controlled trial did not show a significant difference for the primary outcome of lung function, 
however a post-hoc analysis suggested possible benefit in patients not receiving tobramycin. A 
further randomised controlled trial in patients not receiving tobramycin has been reported as 
showing no benefit but has not yet been published in full peer-reviewed form. 
Expert opinion: A small-molecule approach to facilitate read-through of PTCs in nonsense 
mutations makes intuitive sense. However, at present there is no high-quality evidence of clinical 
efficacy for ataluren in people with CF. 
 
 
1.1 Keywords 
ataluren; CFTR; cystic fibrosis; nonsense mutation; PTC 124; read-through agent   
2  Introduction 
 
Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disease in Europe and 
North America 1. In the United Kingdom for example it affects over 10,000 individuals 2. CF is 
characterised by progressive lung disease that ultimately results in end-stage bronchiectasis and 
respiratory failure. Other clinical features include pancreatic insufficiency, CF-related diabetes, 
nutritional compromise, liver dysfunction and male infertility 1. The genetic basis of CF are 
pathogenic mutations in the CF transmembrane conductance regulator (CFTR) gene, which 
encodes for the CFTR transmembrane chloride and bicarbonate channel that is predominantly 
expressed at the apical membrane of epithelial cells 3, 4 . CF is most common in populations of 
Northern European ancestry but also occurs at a lower frequency across ethnically diverse 
populations globally.  
 
Around 2,000 CFTR mutations have been identified of which a small number account for the 
majority of disease 5. CFTR mutations are classified according to the underlying mechanisms 
involved in CFTR protein dysfunction, synthesis and trafficking (Table 1 and Figure 1) 4. Mutations 
causing defective expression of CFTR protein are classified as class I mutations. Class II 
mutations describe dysfunctional CFTR processing and failure of CFTR trafficking to the cell 
surface. In class III mutations, CFTR is expressed at the cell surface but defective nucleotide 
binding leads to impaired channel gating and abnormal epithelial chloride transport. The CFTR 
channel pore is defective in class IV mutations resulting in impaired channel conductance. Splicing 
defects in class V mutations decrease the quantity of correctly transcribed CFTR protein at the cell 
surface. Reduced stability of functional CFTR results in high cell surface turnover in class VI 
mutations. Despite this classification, some mutations are not exclusive to a specific class as 
exemplified by the most common CFTR mutation, Phe508del, which belongs to both classes II 
and III. Furthermore, although classes I to III are associated with a severe disease, phenotypic 
variation within classes and genotypes indicates involvement of multifactorial environmental and 
non-CFTR genetic factors 6.  
 Class I mutations are comprised of a number of mutation types. These include nonsense, 
frameshift and large deletion or insertion mutations that all result in total or partial absence of 
CFTR protein expression7. Class I mutations are therefore functionally characterised by the 
absence of chloride conductance in affected epithelia and a resultant severe disease phenotype. 
Individual CFTR mutation frequency varies globally amongst different ethnic groups 7.  The 
Phe508del CFTR variant accounts for around 70% of mutations in Northern Europe whereas in 
people of Ashkenazi Jewish ancestry class I CFTR mutations are the most common 8.  
 
Development of coordinated multidisciplinary care delivered by specialist centres and guided by 
evidence-based guidelines has yielded incremental improvements in survival as understanding of 
the condition has steadily improved since its first recognition in 1938 9-11. When first described, CF 
was associated with poor survival limited to early childhood; however, median survival is now over 
40 years in countries with well-funded health care systems 12. Traditionally the mainstays of 
treatment have targeted symptoms and attempted to delay disease progression using intensive 
chest physiotherapy, life-long antibiotics, pancreatic enzyme replacement therapy and inhaled 
mucolytics 1. Although clinically successful, none of these strategies have corrected the underlying 
CFTR defect, but rather attempted to ameliorate downstream effects.  
 
Ivacaftor is a small molecule CFTR potentiator that rescues function in class III mutations, most 
notably the Gly551Asp mutation that accounts for around 3-5% of mutant CFTR alleles worldwide 
13. It improved lung function by around 10 percentage points of predicted forced expiratory volume 
in 1 second (FEV1) in multicentre randomised controlled trials with significant benefits in sweat 
chloride, respiratory symptoms, body mass index and quality of life 14, 15. Accordingly, ivacaftor is 
now prescribed as a mutation-specific treatment in many countries. Ivacaftor has provided a 
substantial breakthrough over the last decade for the small cohort of CF patients with eligible 
mutations, is one of the best examples to date of precision medicine and crucially provides ‘proof-
of-concept’ that targeting CFTR dysfunction is likely to be a successful and potentially 
transformative therapeutic strategy 4, 16. Subsequent research and development has focused on 
small molecule approaches to restore function in other common CFTR mutations, most notably 
with the combination treatment (Orkambi™) of lumacaftor, a CFTR corrector, and ivacaftor in 
patients homozygous for Phe508del. However clinical benefits in randomised controlled trials have 
only been modest compared to ivacaftor in Gly551Asp patients and the biology of Phe508del 
CFTR remains complex 17.    
 
Ataluren, also known as PTC-124, is a drug that was identified to specifically target class I 
nonsense CFTR mutations and lead to ‘read-through’ of mRNA resulting in expression of full 
length CFTR protein. This article will review and discuss the background to the development of 
ataluren, its mechanisms of action, and evidence from clinical trials with regard to ataluren as a 
potential treatment in people with CF. 
 
2.1 Overview of the market 
Around 10% of people with CF worldwide have at least one class I nonsense CFTR mutation 18. 
There is, however significant geographical variation; for example in Israel more than 45% of 
patients with CF have a nonsense mutation compared to less than 15% in the UK 7. The most 
common class I mutation is Gly542X 19-21. 
 
2.2 Introduction to the compound – What is ataluren? 
Nonsense mutations give rise to inframe premature termination codons (PTCs) that result in the 
interruption of ribosomal translation and subsequent production of shortened and non-functional 
CFTR protein 7, 22. This activates a regulatory mechanism called nonsense-mediated mRNA decay 
(NMD) that degrades PTC-containing mRNA, reducing further production of shortened proteins. 
Nonsense mutations are defined by PTCs and its regulation via NMD, both of which are 
intrinsically linked 18, 23. Due to an overall lack of functional protein, it follows that patients with this 
class of mutation normally have a severe clinical phenotype.  
 
Therapeutic approaches to CF caused by nonsense mutations include both PTC read-through and 
NMD inhibition 24 to promote production of full-length CFTR, however this article will focus 
specifically on advances in the understanding of PTC read-through with regard to ataluren.  
 
Aminoglycosides were the first class of drugs to demonstrate ribosomal read-through of PTCs 25. It 
is thought that their selectivity to binding-sites on ribosomes causes insertion of a random amino 
acid at the PTC position of mRNA, thus allowing it to read-through the effectively ‘masked’ PTC 
producing a full-length, functioning protein. This exciting observation was first made in the 1960s 
following demonstration of phenotypic repair of defective bacterial genotypes with streptomycin 26. 
From the 1970s, further supporting evidence emerged as this activity of aminoglycosides was 
reproduced in mammalian cells 27. Finally, in 1996, in a pivotal study using CF as a disease 
model, PTC read-through was tested as a novel therapeutic approach by demonstration of full-
length and functioning CFTR protein in cell lines expressing PTCs treated with aminoglycosides 28. 
Indeed, a number of studies since then have shown improvement in CFTR function at a cellular 
level following treatment with gentamicin 29-31. However, parenteral administration and significant 
otic and renal toxicities of this class of drugs limit their clinical usefulness for the purpose of 
restoring CFTR function as a chronic treatment. 
 
Ataluren was identified via high-throughput screening as a compound that similarly promoted read-
through of PTCs 32. It is structurally distinct from aminoglycosides and the first drug in its class 
(Figure 2). The initial discovery was based on demonstration of read-through activity in firefly 
luciferase (FLuc) reporters.  
 
Ataluren has also been investigated in nonsense mutation Duchenne muscular dystrophy 
(nmDMD) and was granted conditional approval for marketing in 2014 by the European Medicines 
Agency (EMA) for this indication following a study showing some clinical benefit in slowing the rate 
of decline in those with advanced disease 33, 34. It is still awaiting US Food and Drug 
Administration (FDA) approval for this indication 35 having initially been filed a Refuse to File letter 
in February 2016 due to lack of convincing evidence of its effectiveness 36. Although more data is 
needed, it provides hope and marks a significant advancement in drug research for this group of 
patients with otherwise no known disease-modifying treatment.  
 
2.3 Chemistry 
Ataluren is a 284 Dalton non-aminoglycoside molecule and its chemical structure (Figure 2) is 
known as 3-[5-(2-fluorophenyl)-[1,2,4]oxa-diazol-3-yl]-benzoic acid (C15H9FN2O3). Its anhydrous 
free carboxylic acid form is orally bioavailable when prepared in aqueous suspension 32.  
 
2.4 Pharmacodynamics 
Several studies in the last decade have studied ataluren’s pharmacodynamic properties and 
mechanism of action with differing results. In a study using cell lines transfected with a firefly 
luciferase gene engineered to have a PTC at codon 190, ataluren demonstrated dose-dependent 
read-through of all three known PTCs (UGA, UAG, UAA) as demonstrated by the amount of 
luciferase activity observed. Compared to gentamicin, ataluren demonstrated potency at much 
lower concentrations 32. In this study, ataluren’s nonsense suppression was demonstrated to be 
due to promotion of PTC read-through activity with minimal effect on the NMD regulatory 
mechanism. Figure 3 schematically summarises the proposed mechanism of action. Ataluren 
demonstrated selectivity to premature but not normal termination codons. Unlike gentamicin, it did 
not demonstrate any antibacterial activity. 
 
A further study published in 2007 shortly after its discovery affirmed its use as a read-through 
agent. In a CF mouse model expressing the Gly542X mutation ataluren treatment resulted in 
expression of CFTR protein at the apical surface of mice intestinal glands, consistent with effective 
in vivo nonsense mutation suppression activity 21. 
 
There are conflicting reports in the scientific literature around the methodology used in ataluren’s 
discovery and mechanisms of action. Two studies used alternative reporter assays and did not 
reproduce evidence of the read-through activity of ataluren 37, 38. These authors suggest that the 
initial observation of ataluren’s read-through ability was instead due to its off-target activity as a 
FLuc inhibitor 37, 38. These studies have faced recent rebuttal however by Roy et al who 
demonstrated read-through activity in several non-luciferase reporter assays. Further evidence 
was provided elucidating ataluren’s selectivity for the ribosomal A site and that it promotes 
insertion of near-cognate tRNAs at the PTC during protein synthesis 39. Roy et al also 
demonstrated that tobramycin (an aminoglycoside with similar ribosomal selectivity) is a strong 
inhibitor of ataluren, consistent with a previous hypothesis proposed by Kerem et al in a post-hoc 
in vitro study as part of a phase III trial (see further discussion below) 40. 
 
The ex vivo human intestinal organoid model has also been used to further investigate the 
functional effects of ataluren. In this model, intestinal epithelial cells derived from rectal biopsy 
tissue are cultured to produce organoids that contain crypt-like structures and a central lumen 
lined by a CFTR-expressing differentiated apical epithelium. Addition of forskolin, a potent 
activator of CFTR, can be used to assess the effects of CFTR activity on fluid secretion via 
assessment of organoid swelling. In this study, intestinal organoids were derived from compound 
heterozygous patients for 5 nonsense mutations in combination with either a frameshift mutation 
or Phe508del 41. Pre-treatment with ataluren in isolation or combination with ivacaftor and 
lumacaftor did not result in either total organoid or luminal swelling in all donor organoids, 
indicating its failure to induce detectable read-through in this model 41. 
 
2.5 Pharmacokinetics and metabolism 
Phase I and II studies have demonstrated rapid oral absorption of ataluren and dose-proportional 
increases in pharmacokinetic parameters with absence of any significant gender or age effects 42-
44. Peak ataluren plasma levels are achieved at approximately 2 hours after dosing and its half-life 
ranges between 3 to 6 hours. With multiple dosing, there was no evidence of drug accumulation or 
metabolic auto-induction. Phase I studies have also observed that the percentage of ataluren 
excreted in the urine as the parent drug is low 42. 
 2.6 Clinical efficacy 
As with all studies discussed in this section, participants included those with two disease-causing 
CFTR mutations with at least one being a class I nonsense mutation. 
 
2.61 Phase II studies 
An initial phase II study was performed in 23 adults 43. In this prospective open-label crossover 
trial, participants received 2 cycles of treatment. 23 participants were included in the first cycle but 
only 21 in the second. Each cycle comprised a 14-day treatment period (first: 16mg/kg/day; 
second: 40mg/kg/day) followed by a 14-day washout period. No placebo was used during the 
washout period.  
 
The primary outcome was treatment response as measured by nasal PD. Nasal PD was used as a 
surrogate measure of the presence and function of CFTR protein on respiratory epithelial cell 
surfaces. Measurement of nasal PD involves sequential perfusion of compounds across the nasal 
epithelial surface, initially blocking absorption of sodium and subsequently augmenting CFTR-
mediated chloride transport. This sequence results in dynamic changes in potential difference, 
with eventual hyperpolarisation. The most consistent abnormality in CF is the absence of this 
hyperpolarisation 45. A good response was pre-defined as an increase in total chloride transport by 
-5mV or more. Normal chloride transport was predefined as nasal PD that is at least as electrically 
negative as -5mV. Patients were used as their own control based on the premise that all 
participants had an abnormal baseline nasal PD and that fewer than 5% of nonsense mutation CF 
patients have been found to have nasal PD values corresponding to that of ‘hyperpolarisers’ 29, 43. 
  
Improvement in total chloride transport was seen in the majority of patients in both cycles, see 
Table 2. In a proportion of these, total chloride transport entered the normal range: 13 patients 
(57%) in the first cycle (p=0.0003) compared to 9 patients (43%) in the second cycle (p=0.02).  
These improvements reverted to baseline values during 14 days off treatment, suggesting that the 
effect observed was mediated by ataluren. A small increase in FEV1 (actual numerical values not 
included in the original paper; p=0.037) and bodyweight with a mean change of +0.6kg (SD 0.6; 
p<0.0001) were seen only in the first phase of treatment. 
A follow-on open-label study was performed in 19 of the initial participants of the above trial 
evaluating the effects of 12 weeks of continuous treatment 46. Patients were allocated to the 
dosing regimen in which their best response was observed in the prior study. They demonstrated 
statistically significant ongoing improvement in total chloride transport, see Table 2. This 
improvement was progressive with increasing duration of treatment but was not dose-dependent.  
 
A subsequent phase II prospective crossover trial was the first to look at the same primary 
outcome in children involving 30 participants aged 6 to 18 years 44. They were randomised to two 
cohorts (high-to-low dosing versus low-to-high dosing) and were assessed similarly in 2 cycles of 
14 days on treatment and 14 days off.  Using nasal PD, a total chloride response was seen in 50% 
of patients (n=15). 47% of patients (n=14) were observed to enter the normal range of total 
chloride transport, with higher rates observed in higher dose levels in both cohorts. Using 
immunohistochemistry, this study was also the first to observe increased apical CFTR protein 
expression on nasal epithelial cells post-treatment although this could not be correlated with 
changes in nasal PD due to small sample size and variability in measurements. Again, no 
statistically significant changes were seen in clinical outcomes such as FEV1 and body weight. 
Encouragingly, this study also demonstrated its safety for use in a paediatric cohort. 
 
In each of these studies no association was demonstrated between treatment response and any 
particular genotype or genotype combination. Notably, all the phase II studies had a small sample 
size and with a relatively short trial period and crossover design, they are not ideal for studying 
long-term clinical outcomes of a potentially disease-modifying drug. 
 
2.62 Phase III studies 
The above studies paved the way for a phase III multi-centre randomised controlled trial that was 
performed in a larger cohort of 238 patients aged 6 years or over 40. Patients were randomised to 
receive ataluren (40mg/kg/day in three divided doses) or placebo for 48 weeks. The primary 
outcome was change in percentage predicted FEV1 with rate of pulmonary exacerbations as a 
secondary outcome. Overall there was no significant difference in mean relative change in FEV1 at 
48 weeks between the treatment groups with a mean difference of 1.76% in favour of ataluren 
(95% CI -0.43, 3.95) 40, 47. The mean rate of pulmonary exacerbations was lower in the ataluren-
treated group compared to placebo (rate ratio 0.77; p=0.099) across the 48 weeks but this was not 
statistically significant. Similar to the phase II studies, there were also no changes seen in sweat 
chloride concentrations, which was an exploratory outcome of this study 43, 44, 46.  No significant 
difference in total chloride transport, as measured by nasal PD was detected post-treatment.  
 
A post-hoc analysis was performed on the subgroup of patients receiving chronic inhaled 
tobramycin versus those not receiving it. This analysis, which a Cochrane review identified as 
being at high risk of bias for selective reporting, suggested that in patients not receiving 
tobramycin, the mean relative change in percentage predicted FEV1 at week 48 was 5.7% in 
favour of ataluren (95% CI 1.5 to 10.1; p=0.024) 47. It was also demonstrated in vitro using a 
luciferase reporter assay that ataluren-induced readthrough is diminished when cells are co-
incubated with a combination of ataluren and the aminoglycoside antibiotics gentamicin or 
tobramycin 40.  
 
To investigate these observations a further phase III study (ClinicalTrials.gov identifier 
NCT02139306) involving 279 patients not receiving chronic inhaled tobramycin was performed. In 
March 2017 an announcement was made via a PTC Therapeutics press release stating that the 
results of this trial showed similar failure to reach the same primary and secondary endpoints. 
Note that at the time of writing, the full data remains unpublished. However, the announcement 
reported in brief that the change in percentage predicted FEV1 was 0.6% in favour of ataluren 
(p=0.534) and the rate of pulmonary exacerbations was 14% lower in the ataluren group (p=0.401) 
but neither of these results were statistically significant. In light of these discouraging results PTC 
Therapeutics have recently decided to discontinue their clinical development of ataluren for CF 48 . 
 
2.7 Safety and tolerability 
Preclinical pharmacology studies in rats and dogs have demonstrated that oral administration of 
ataluren at high doses (up to 1500mg/kg) did not induce any neurological, pulmonary or 
cardiovascular toxicities 42. All human phase II studies have not shown any clinically significant 
adverse effects potentially attributed to ataluren, however none of these studies were placebo-
controlled. Most adverse events were reported as mild to moderate, and none showed a dose-
dependent increase in frequency or severity. In the first phase II trial in adults, the most common 
adverse event was dysuria (n=4) but this was not accompanied by any urinary abnormalities 43 . 
This observation was not seen in the ensuing trial in children 44. Blood markers of renal and liver 
function, such as creatinine and levels of aminotransferases were stable throughout the phase II 
studies.  
 
Importantly in the first phase III trial there were significantly more episodes of acute kidney injury, 
reported as renal failure, acute renal failure, renal impairment or hyper-creatininaemia, in the 
ataluren group (RR 17.70 CI 1.28 to 244.40) 40. The authors attributed cases of acute kidney injury 
in the ataluren arm to concomitant use of systemic nephrotoxic antibiotics (aminoglycosides and 
vancomycin) and dehydration. This was addressed by amendment of the study protocol, at 7 
months, to prohibit ataluren use with these systemic antibiotics and encouraging hydration.  
 
Ataluren was generally well tolerated across all studies by participants and compliance was not a 
major issue. 
 
2.8 Regulatory affairs 
The rights to ataluren are owned by PTC Therapeutics and it is marketed under the trade name 
Translarna™. Ataluren is approved within the European Union Member States for the treatment of 
nmDMD in ambulatory patients aged over 5 years. It is designated as an orphan medicinal product 
by the EMA and the US FDA has granted orphan drug designation to ataluren for the treatment of 
nmDMD. 
  
2.9 Conclusion 
Class I nonsense CFTR mutations are present in around 10% of people with CF worldwide and 
are associated with a severe clinical phenotype due to absence of full-length functional CFTR 
protein. Ataluren is an orally administered small-molecule drug that facilitates the read-through of 
mRNA beyond a PTC thereby allowing expression of full-length protein. There is in vitro evidence 
that ataluren facilitates read-through in cellular models expressing nonsense CFTR mutations. 
Early phase cross over studies in patients with nonsense CFTR mutations also showed favourable 
changes in electrophysiology in terms of nasal PD with short-term ataluren treatment. However, 
phase III randomised, blinded and placebo-controlled clinical trials on two occasions have not 
shown benefit from ataluren treatment and at present there is no high-quality evidence of clinical 
efficacy in patients. It is important to note that the most recent RCT has not been formally 
published in a peer-reviewed format and we base our comments on a press release from PTC 
Therapeutics 48.  
 
2.10 Expert opinion 
The story to date of the identification of ataluren and subsequent development and evaluation as a 
potential treatment in people with CF caused by class I nonsense CFTR mutations is a fascinating 
one from an academic and clinical perspective. It began with exciting discovery science and the 
identification of a small-molecule able to facilitate the translation of full-length protein and nullify 
the basic problem caused by pathogenic PTCs. In the laboratory/basic science world there was 
subsequently some controversy about its true mechanism of action and how best to study this with 
the most recent publication confirming in vitro efficacy.  
 
Using changes in nasal PD as a read out of CFTR function short-term cross over studies in adults 
and children with CF caused by class I nonsense CFTR mutations showed some positive effects. 
Appropriately large multi-centre RCTs were subsequently performed with the first study essentially 
being negative aside from a post-hoc analysis of participants not receiving tobramycin. The 
scientific rationale as to why tobramycin may be relevant here provided fresh hope and a further 
RCT was performed in patients not receiving tobramycin. The full results of this trial are yet to be 
formally published in a peer-reviewed journal but we understand based on a press release from 
PTC Therapeutics that they are negative and that the company are no longer pursuing ataluren as 
a treatment in CF. It has to be our opinion therefore that there is no good-quality evidence of 
clinical efficacy for ataluren in CF.  With the benefit of hindsight, the current evidence would now 
suggest that data associated with the post-hoc analysis from the group not receiving tobramycin 
was not strong enough to base a further phase III study on. 
 
We suspect that from a patient’s perspective it is a particularly frustrating and disappointing story. 
The therapeutic approach of using a small-molecule to facilitate read-through and expression of 
full-length functional CFTR protein is sound and worthy of continued investigation in our opinion. 
On reflection the ataluren experience to date illustrates a number of key points for CF research; 
firstly, the importance of ongoing basic science using the most valid experimental models and 
secondly the crucial importance of careful study design in translational CF research. There are 
ongoing challenges around which endpoints are most relevant in early phase versus later phase 
studies in CF and these feed in to the difficulties in conducting appropriately powered phase III 
studies in subsets of people who have what is regarded as an orphan disease.49   
   
2.11 Drug summary box 
Drug name PTC-124 or Ataluren 
Phase (for indication under discussion) Second Phase III trial 
(awaiting publication of results; 
ClinicalTrials.gov identifier NCT02139306) 
Indication (specific to discussion) Patients with nonsense mutation cystic fibrosis 
Pharmacology description/mechanism of action Enables ribosomal read-through of PTCs hence 
restoring production of full length and functional 
CFTR protein 
Route of administration Oral 
Chemical structure 3-[5-(2-fluorophenyl)-[1,2,4]oxa-diazol-3-yl]-
benzoic acid (C15H9FN2O3) 
Pivotal trials Phase II trials  
 Kerem et al 2008 43 
 Sermet-Gaudelus et al 2010 44 
 Wilschanski et al 2011 46 
Phase III trials 
 Kerem et al 2014 40 
 ACT CF Trial (ClinicalTrials.gov identifier 
NCT02139306) 48 
 
 
  
Table 1. Different functional classes of CFTR pathogenic mutations and relevant 
therapeutic strategies. 
 
 
  
Mutation class Nature of defect  Example Relevant therapeutic 
strategies 
Class I Protein synthesis  Gly542X Read-through compounds 
(Ataluren) 
Class II Protein processing and 
trafficking 
Phe508del Corrector plus potentiator   
(Lumacaftor + Ivacafor)) 
Class III Channel gating Gly551Asp Potentiator  
(Ivacaftor) 
Class IV Channel conductance Arg117His Potentiator  
(Ivacaftor) 
Class V Reduced protein production 3849 + 10 kb 
C  T 
Non-approved strategies: 
Antisense oligonucleotides 
Correctors 
Potentiators 
Class VI High turnover of unstable 
protein at cell surface 
c. 120del23 None available 
Table 2. Summary of published clinical trials of ataluren in people with cystic fibrosis 
 
Study  Kerem et al 2008 
43 
Sermet-
Gaudelus et al 
2010 44 
Wilschanski et al 
2011 46 
Kerem et al 2014 
40 
Design Phase 2  
Non-randomised 
Open-label 
Single group 
assignment 
Crossover 
Phase 2 
Randomised 
Open-label 
Parallel 
assignment 
Crossover 
No placebo 
Phase 2 
extension 
Non-randomised 
Open-label 
Parallel 
assignment 
No placebo 
Phase 3 
multicenter 
Randomised 
Double-blind 
Parallel 
assignment 
Placebo-
controlled 
Sample size 23 30 19 238 
Duration 2 x 28 day cycles 
 
Cycle 1: 
16mg/kg/day for 
14 days;  
no treatment for 
14 days 
 
Cycle 2:  
20mg/kg/day for 
14 days;  
no treatment for 
14 days 
2 x 28 day cycles 
 
14 days on 
treatment 
14 days off 
treatment 
 
Cycle 1 
treatment 
Either 
16mg/kg/day or 
20mg/kg/day 
 
Cycle 2 
treatment 
Opposite 
regimen to that 
in 1st cycle 
12 weeks 
 
Group 1 
16mg/kg/day 
 
Group 2  
20mg/kg/day 
48 weeks 
 
Group 1 
40mg/kg/day 
 
Group 2 
Placebo 
Inclusion 
criteria 
Age ≥ 18 years 
 
Sweat chloride > 
40mEq/L 
 
Nasal PD > -5mV 
 
2 disease CFTR 
mutations,  
≥1 nonsense 
 
FEV1≥40% 
 
O2 saturations 
≥92% in air 
Age 6-18 years 
 
Sweat chloride > 
40mEq/L 
 
Nasal PD > -
5mV 
 
2 disease CFTR 
mutations,  
≥1 nonsense 
 
FEV1≥40% 
 
O2 saturations 
≥92% in air 
Age ≥ 18 years 
 
Sweat chloride > 
40mEq/L 
 
Nasal PD > -
5mV 
 
2 disease CFTR 
mutations, ≥1 
nonsense 
 
FEV1≥40% 
 
O2 saturations 
≥92% in air 
Age ≥ 6 years 
 
Sweat chloride > 
40mEq/L 
 
Nasal PD > -5mV 
 
2 disease CFTR 
mutations, ≥1 
nonsense 
 
40%≤FEV1≤90% 
 
O2 saturations 
≥92% in air 
 
 Weight ≥25kg 
Weight≥16kg 
Primary 
outcome 
CFTR activity 
(nasal PD) 
CFTR activity 
(nasal PD) 
CFTR activity 
(nasal PD) 
FEV1 
Mean FEV1 Small increase in 
1st cycle of 
treatment 
P=0.037 
No improvement No significant 
difference 
No significant 
difference 
Total chloride 
transport 
(measured by 
nasal PD) 
Cycle 1 
-7.1mV 
(p<0.0001) 
 
Cycle 2 
-3.7mV (p=0.032) 
Low to high 
dosing 
-4.6mV 
(p=0.037) 
 
High to low 
dosing 
-3.9mV 
(p=0.046) 
Group 1 
-6.8mV 
(p=0.004) 
 
Group 2 
-3.4mV 
(p=0.025) 
No significant 
difference  
Sweat 
chloride 
No change - - No significant 
difference 
Pulmonary 
exacerbations 
- - - Ataluren 1.42 
Placebo 1.78 
 
Rate ratio 0.77 
(p=0.0992) 
Weight Mean change 
+0.6kg 
(p<0.0001) 
No improvement - No significant 
difference 
 
 
  
Figure legends 
Figure 1. Schematic diagram illustrating different functional classes of CFTR mutation. 
CFTR mutations are classified into 1 of 6 classes based on the mechanisms underlying CFTR 
protein dysfunction. Class I mutations lead to the formation of a truncated CFTR protein, Class II 
mutations result in dysfunctional CFTR processing and transport. Class III – VI mutations are 
expressed apically; however, Class III mutations feature defective CFTR gating, in Class IV 
mutations the CFTR channel pore is defective, Class V mutations result in a splicing defect limiting 
the amount of CFTR protein produced and Class VI mutations result in increased CFTR protein 
turnover.Figure adapted from Brodlie et al, 2015 22 
 
Figure 2. Chemical structure of ataluren. 
 
Figure 3. Schematic diagram of mechanism of action of ataluren. 
In health a) full length CFTR protein is transcribed from the CFTR mRNA, processed and 
transported to the apical membrane of airway and other epithelial cells. At the apical membrane 
CFTR modulates chloride, and other, ion transport maintaining ASL homeostasis; promoting 
mucociliary clearance and anti-microbial activity inhibiting pathogen colonisation. Class I CFTR 
mutations (e.g. Gly542X) b) result in the translation of a truncated CFTR protein, due to nonsense, 
frameshift or insertion/deletion mutations introducing a premature stop codon. This truncated 
CFTR is non-functional and is rapidly degraded. The absence of CFTR at the apical membrane 
leads to a lack of chloride, and other ion, transport altering ASL homeostasis; leading to 
mucostasis, impaired anti-microbial activity giving rise to the pathology of CFLD. Ataluren c) is 
thought to interact with the ribosome to promote read-through of premature stop codons. In Class I 
CFTR mutations this read-through capacity is proposed to facilitate the translation of full length, 
functional CFTR, thereby restoring a proportion of its apical activity. 
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